AR014514A1 - AN ISOLATED POLINUCLEOTIDE; AN ISOLATED POLYPEPTIDE CODED BY SUCH POLINUCLEOTIDE; AN EXPRESSION VECTOR THAT INCLUDES SUCH POLINUCLEOTIDE; A TRANSFORMED UNCELL WITH SUCH EXPRESSION VECTOR; A PHARMACEUTICAL COMPOSITION AND A VACCINE THAT UNDERSTAND THE POLYPEPTIDE FOR THE TREATMENT OF CANCE - Google Patents
AN ISOLATED POLINUCLEOTIDE; AN ISOLATED POLYPEPTIDE CODED BY SUCH POLINUCLEOTIDE; AN EXPRESSION VECTOR THAT INCLUDES SUCH POLINUCLEOTIDE; A TRANSFORMED UNCELL WITH SUCH EXPRESSION VECTOR; A PHARMACEUTICAL COMPOSITION AND A VACCINE THAT UNDERSTAND THE POLYPEPTIDE FOR THE TREATMENT OF CANCEInfo
- Publication number
- AR014514A1 AR014514A1 ARP990100346A ARP990100346A AR014514A1 AR 014514 A1 AR014514 A1 AR 014514A1 AR P990100346 A ARP990100346 A AR P990100346A AR P990100346 A ARP990100346 A AR P990100346A AR 014514 A1 AR014514 A1 AR 014514A1
- Authority
- AR
- Argentina
- Prior art keywords
- polinucleotide
- isolated
- polypeptide
- expression vector
- polynucleotides
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Physics & Mathematics (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Plant Pathology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Polinucleotidos aislados que codifican polipéptidos de tumor de pulmon. Estos polinucleotidos comprenden una secuencia de nucleotidos seleccionada delgrupo consistente en: (a) secuencias provistas en SEQ. ID. NO.: 1-11, 19, 22- 25, 27-31, 51, 53, 55, 63, 70, 72, 79, 80, 86, 87, 89, 90, 102-107, 109, 139,143-149, 151-154, y 156-158; (b) secuencias complementarias para una secuencia provista en SEQ. ID. NO.: 1-11, 19, 22-25, 27-31, 51, 53, 55, 63, 70, 72, 79,80, 86, 89, 90, 102-107, 109, 139, 143-149, 151-154, y 156-158; y (c) variantes de las secuencias de (a) y (b). Los polipéptidos aislados comprenden al menosuna porcion inmunogénica de una proteína de tumor pulmonar, o de una variante de ella. Vectores de expresion que comprendenlos polinucleotidos; célulashuéspedes transformadas o transinfectadas con estos vectores de expresion. Las proteínas de fusion comprenden un primer y un segundo polipéptido, o bien, elpolipéptido y un antígeno de tumor de pulmon conocido. Las composiciones farmacéuticas comprenden uno o más de los polipéptidos codificados por unpolinucleotido que comprende una secuencia seleccionada del grupo que consiste de (a) secuencias provistas en SEQ. ID. NO.: 1 a 181; (b) complementos de lassecuencias provistas en SEQ. ID. NO.: 1 a 181; (c) variantes de las secuencias de (a) y (b); proteínas de fusion, o polinucleotidos, y un vehículofisiologicamente aceptable. Las vacunas comprenden uno o más de los polipéptidos, proteínas de fusion, o polinucleotidos, combinados con unmejorador de respuesta inmune. Los métodos para inhibir el desarrollo de cáncer de pulmon en un paciente consisten en administrar a un paciente una cantidadeficaz de al menos una de las composiciones farmacéuticas y/o vacunas mencionadas. Métodos para detectar cáncer de pulmon en un paciente consisten enIsolated polynucleotides encoding lung tumor polypeptides. These polynucleotides comprise a nucleotide sequence selected from the group consisting of: (a) sequences provided in SEQ. ID. NO .: 1-11, 19, 22-25, 27-31, 51, 53, 55, 63, 70, 72, 79, 80, 86, 87, 89, 90, 102-107, 109, 139,143-149 , 151-154, and 156-158; (b) complementary sequences for a sequence provided in SEQ. ID. NO .: 1-11, 19, 22-25, 27-31, 51, 53, 55, 63, 70, 72, 79.80, 86, 89, 90, 102-107, 109, 139, 143-149 , 151-154, and 156-158; and (c) variants of the sequences of (a) and (b). Isolated polypeptides comprise at least one immunogenic portion of a lung tumor protein, or a variant thereof. Expression vectors comprising polynucleotides; Guests transformed or transinfected with these expression vectors. Fusion proteins comprise a first and a second polypeptide, or the polypeptide and a known lung tumor antigen. The pharmaceutical compositions comprise one or more of the polypeptides encoded by a polynucleotide comprising a sequence selected from the group consisting of (a) sequences provided in SEQ. ID. NO .: 1 to 181; (b) complements of the sequences provided in SEQ. ID. NO .: 1 to 181; (c) variants of the sequences of (a) and (b); fusion proteins, or polynucleotides, and a physiologically acceptable vehicle. Vaccines comprise one or more of the polypeptides, fusion proteins, or polynucleotides, combined with an immune response enhancer. The methods for inhibiting the development of lung cancer in a patient consist in administering to a patient an effective amount of at least one of the pharmaceutical compositions and / or vaccines mentioned. Methods to detect lung cancer in a patient consist of
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US1502298A | 1998-01-28 | 1998-01-28 | |
US1502998A | 1998-01-28 | 1998-01-28 | |
US4083198A | 1998-03-18 | 1998-03-18 | |
US4082898A | 1998-03-18 | 1998-03-18 | |
US12219298A | 1998-07-23 | 1998-07-23 | |
US12219198A | 1998-07-23 | 1998-07-23 | |
US21924598A | 1998-12-22 | 1998-12-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR014514A1 true AR014514A1 (en) | 2001-02-28 |
Family
ID=27567530
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP990100346A AR014514A1 (en) | 1998-01-28 | 1999-01-28 | AN ISOLATED POLINUCLEOTIDE; AN ISOLATED POLYPEPTIDE CODED BY SUCH POLINUCLEOTIDE; AN EXPRESSION VECTOR THAT INCLUDES SUCH POLINUCLEOTIDE; A TRANSFORMED UNCELL WITH SUCH EXPRESSION VECTOR; A PHARMACEUTICAL COMPOSITION AND A VACCINE THAT UNDERSTAND THE POLYPEPTIDE FOR THE TREATMENT OF CANCE |
Country Status (13)
Country | Link |
---|---|
EP (1) | EP1051489A2 (en) |
JP (1) | JP2002516659A (en) |
KR (1) | KR20010034436A (en) |
CN (1) | CN1292029A (en) |
AR (1) | AR014514A1 (en) |
AU (1) | AU2344399A (en) |
BR (1) | BR9907259A (en) |
CA (1) | CA2319117A1 (en) |
ID (1) | ID27813A (en) |
IL (1) | IL137417A0 (en) |
NO (1) | NO20003853L (en) |
WO (1) | WO1999038973A2 (en) |
ZA (1) | ZA99693B (en) |
Families Citing this family (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6312695B1 (en) | 1998-03-18 | 2001-11-06 | Corixa Corporation | Compounds and methods for therapy of lung cancer |
US6821518B1 (en) | 1998-03-18 | 2004-11-23 | Corixa Corporation | Compounds and methods for therapy and diagnosis of lung cancer |
US6660838B1 (en) | 1998-03-18 | 2003-12-09 | Corixa Corporation | Compounds and methods for therapy and diagnosis of lung cancer |
US6531315B1 (en) | 1998-03-18 | 2003-03-11 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
US6518256B1 (en) | 1998-03-18 | 2003-02-11 | Corixa Corporation | Compounds and methods for therapy and diagnosis of lung cancer |
US7049063B2 (en) | 1998-03-18 | 2006-05-23 | Corixa Corporation | Methods for diagnosis of lung cancer |
US6737514B1 (en) | 1998-12-22 | 2004-05-18 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
US6482597B1 (en) | 1999-12-17 | 2002-11-19 | Corixa Corporation | Compounds and methods for therapy and diagnosis of lung cancer |
US7258860B2 (en) | 1998-03-18 | 2007-08-21 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
US6960570B2 (en) | 1998-03-18 | 2005-11-01 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
US7579160B2 (en) | 1998-03-18 | 2009-08-25 | Corixa Corporation | Methods for the detection of cervical cancer |
US6696247B2 (en) | 1998-03-18 | 2004-02-24 | Corixa Corporation | Compounds and methods for therapy and diagnosis of lung cancer |
US6706262B1 (en) | 1998-03-18 | 2004-03-16 | Corixa Corporation | Compounds and methods for therapy and diagnosis of lung cancer |
US6426072B1 (en) | 2000-08-02 | 2002-07-30 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
EP0987552A3 (en) * | 1998-08-31 | 2000-06-07 | Pfizer Products Inc. | Diarylsulfonylurea binding proteins |
EP1526383A3 (en) * | 1998-08-31 | 2005-11-16 | Pfizer Products Inc. | Diarylsulfonylurea binding proteins |
AU766809B2 (en) * | 1998-10-28 | 2003-10-23 | Rigel Pharmaceuticals, Inc. | Novel compositions and methods of screening for T-cell and B-cell activation modulators |
US6709855B1 (en) | 1998-12-18 | 2004-03-23 | Scios, Inc. | Methods for detection and use of differentially expressed genes in disease states |
WO2000035473A2 (en) * | 1998-12-18 | 2000-06-22 | Scios Inc. | Methods for detection and use of differentially expressed genes in disease states |
WO2000046370A1 (en) * | 1999-02-04 | 2000-08-10 | Board Of Trustees Of The University Of Illinois | P37ing1 compositions and methods of use |
US6544946B1 (en) | 1999-02-19 | 2003-04-08 | Zymogenetics, Inc. | Inhibitors for use in hemostasis and immune function |
BR0008298A (en) | 1999-02-19 | 2002-02-19 | Zymogenetics Inc | Methods to promote blood flow within a mammal's vasculature, to pacify damaged collagenous tissues within a mammal, to pacify the surface of a prostatic biomaterial for use in association with a mammal, and to mediate wound repair in a mammal |
US6759508B2 (en) | 2000-09-01 | 2004-07-06 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
US6444425B1 (en) | 1999-04-02 | 2002-09-03 | Corixa Corporation | Compounds for therapy and diagnosis of lung cancer and methods for their use |
KR20020007354A (en) * | 1999-04-02 | 2002-01-26 | 길리스 스티브 | Compounds and methods for therapy and diagnosis of lung cancer |
WO2000060077A2 (en) * | 1999-04-02 | 2000-10-12 | Corixa Corporation | Compounds for therapy and diagnosis of lung cancer and methods for their use |
US20030211510A1 (en) | 1999-06-30 | 2003-11-13 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
US6509448B2 (en) | 1999-06-30 | 2003-01-21 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
US6914132B1 (en) | 1999-06-30 | 2005-07-05 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
US6746846B1 (en) | 1999-06-30 | 2004-06-08 | Corixa Corporation | Methods for diagnosing lung cancer |
US6686447B1 (en) | 1999-06-30 | 2004-02-03 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
US6504010B1 (en) | 1999-06-30 | 2003-01-07 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
US6858204B2 (en) | 1999-06-30 | 2005-02-22 | Corxia Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
US20030125245A1 (en) | 1999-06-30 | 2003-07-03 | Tongtong Wang | Compositions and methods for therapy and diagnosis of lung cancer |
US6667154B1 (en) | 1999-06-30 | 2003-12-23 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
CZ20014718A3 (en) | 1999-06-30 | 2003-01-15 | Corixa Corporation | Compounds and methods for therapy and diagnostic of lung cancer |
CA2309313A1 (en) * | 1999-08-05 | 2001-02-05 | Board Of Trustees Of The University Of Arkansas | Stimulation of the immune response by human dendritic cell manipulation |
WO2001021653A2 (en) * | 1999-09-23 | 2001-03-29 | Corixa Corporation | Ovarian tumor antigen and methods of use therefor |
EP1672070A3 (en) * | 1999-12-01 | 2006-10-04 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
AU2001253388A1 (en) * | 2000-04-14 | 2001-10-30 | Incyte Genomics, Inc. | Molecules associated with human reproduction |
EP1366157A2 (en) * | 2000-06-29 | 2003-12-03 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
CA2415544A1 (en) * | 2000-07-11 | 2002-01-17 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
AU2001270638A1 (en) * | 2000-07-19 | 2002-01-30 | Bayer Aktiengesellschaft | Regulation of human airway trypsin protease-like enzyme |
DE60130782T2 (en) * | 2000-08-28 | 2008-07-03 | Teijin Ltd. | AIRWAY-SPECIFIC, TRYPSIN-SIMILAR ENZYMES AND METHODS FOR THEIR APPLICATION |
WO2002055694A2 (en) | 2001-01-16 | 2002-07-18 | Genset Sa | Discriminative nucleic acid analysis using clone sequence signatures |
GB0101300D0 (en) * | 2001-01-18 | 2001-02-28 | Univ Cambridge Tech | Primordial germ cell genes |
US7226994B2 (en) | 2001-01-18 | 2007-06-05 | Cambridge University Technical Services Limited | Cell surface expressed marker of pluripotency |
US20050085627A1 (en) | 2001-06-21 | 2005-04-21 | Youming Zhang | Atopy |
US20040081653A1 (en) * | 2002-08-16 | 2004-04-29 | Raitano Arthur B. | Nucleic acids and corresponding proteins entitled 251P5G2 useful in treatment and detection of cancer |
AU2007216892B2 (en) * | 2002-08-16 | 2011-02-10 | Agensys, Inc. | Nucleic acids and corresponding proteins entitled 273P4B7 useful in treatment and detection of cancer |
EP1583548A4 (en) * | 2002-12-10 | 2007-10-17 | Epimmune Inc | Hla-a1, a2 -a3,-a24,-b7,and -b44 tumor associated antigen peptides and compositions |
US20060252057A1 (en) * | 2004-11-30 | 2006-11-09 | Mitch Raponi | Lung cancer prognostics |
ES2531142T3 (en) | 2005-10-17 | 2015-03-11 | Sloan Kettering Inst Cancer | Class II HLA binding WT1 peptides, and compositions and methods comprising them |
EP3117836A1 (en) | 2006-04-10 | 2017-01-18 | Sloan Kettering Institute For Cancer Research | Immunogenic wt-1 peptides and uses thereof |
EP2423332A1 (en) * | 2006-08-25 | 2012-02-29 | Oncotherapy Science, Inc. | Prognostic markers and therapeutic targets for lung cancer |
US20110236314A1 (en) * | 2008-09-12 | 2011-09-29 | Cancer Research Initiatives Foundation | Method of detection and diagnosis of oral and nasopharyngeal cancers |
CN101891802B (en) * | 2009-08-11 | 2011-11-16 | 武汉凯泰新生物技术有限公司 | Polypeptide or derivative product for treating or preventing cancer and application thereof |
CN101921313B (en) * | 2010-04-07 | 2012-02-29 | 武汉凯泰新生物技术有限公司 | Polypeptide for curing or preventing cancer or derivative product and application thereof |
GB201104286D0 (en) * | 2011-03-15 | 2011-04-27 | Randox Lab Ltd | Glutathione S-transferase omega 1 wild type specific antibody |
US9644026B2 (en) * | 2011-09-09 | 2017-05-09 | Trans Genic Inc. | Antibody against mutant α-actinin-4 |
EP3520810A3 (en) | 2012-01-13 | 2019-11-06 | Memorial Sloan-Kettering Cancer Center | Immunogenic wt1 peptides and use thereof |
US10815273B2 (en) | 2013-01-15 | 2020-10-27 | Memorial Sloan Kettering Cancer Center | Immunogenic WT-1 peptides and methods of use thereof |
LT2945647T (en) | 2013-01-15 | 2021-02-25 | Memorial Sloan Kettering Cancer Center | Immunogenic wt-1 peptides and methods of use thereof |
CN109476721B (en) * | 2016-04-04 | 2022-06-28 | 英蒂分子公司 | CD 8-specific capture agents, compositions and methods of use and preparation |
CN110139927B (en) * | 2016-11-16 | 2024-06-07 | 加利福尼亚大学董事会 | CRISPR-CAS9 inhibitors |
CN110669104B (en) * | 2019-10-30 | 2021-11-05 | 上海交通大学 | Group of markers derived from human peripheral blood mononuclear cells and application thereof |
CN112500467B (en) * | 2020-12-14 | 2022-05-24 | 上海交通大学 | Bioactive peptide RRECPSDECGAGVF, and preparation method and application thereof |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5589579A (en) * | 1994-07-19 | 1996-12-31 | Cytoclonal Pharmaceutics, Inc. | Gene sequence and probe for a marker of non-small cell lung carinoma |
US5633161A (en) * | 1995-03-29 | 1997-05-27 | Millennium Pharmaceuticals, Inc. | Murine gene fomy030 coding for tumor progression inhibitor |
-
1999
- 1999-01-20 ID IDW20001646A patent/ID27813A/en unknown
- 1999-01-26 JP JP2000529432A patent/JP2002516659A/en not_active Withdrawn
- 1999-01-26 KR KR1020007008209A patent/KR20010034436A/en not_active Application Discontinuation
- 1999-01-26 AU AU23443/99A patent/AU2344399A/en not_active Abandoned
- 1999-01-26 EP EP99903417A patent/EP1051489A2/en not_active Withdrawn
- 1999-01-26 CN CN99803446A patent/CN1292029A/en active Pending
- 1999-01-26 BR BR9907259-9A patent/BR9907259A/en not_active Application Discontinuation
- 1999-01-26 IL IL13741799A patent/IL137417A0/en unknown
- 1999-01-26 WO PCT/US1999/001642 patent/WO1999038973A2/en not_active Application Discontinuation
- 1999-01-26 CA CA002319117A patent/CA2319117A1/en not_active Abandoned
- 1999-01-28 ZA ZA9900693A patent/ZA99693B/en unknown
- 1999-01-28 AR ARP990100346A patent/AR014514A1/en unknown
-
2000
- 2000-07-27 NO NO20003853A patent/NO20003853L/en unknown
Also Published As
Publication number | Publication date |
---|---|
EP1051489A2 (en) | 2000-11-15 |
WO1999038973A3 (en) | 1999-12-09 |
NO20003853D0 (en) | 2000-07-27 |
BR9907259A (en) | 2002-01-22 |
IL137417A0 (en) | 2001-07-24 |
ID27813A (en) | 2001-04-26 |
KR20010034436A (en) | 2001-04-25 |
CN1292029A (en) | 2001-04-18 |
JP2002516659A (en) | 2002-06-11 |
CA2319117A1 (en) | 1999-08-05 |
AU2344399A (en) | 1999-08-16 |
NO20003853L (en) | 2000-09-27 |
WO1999038973A2 (en) | 1999-08-05 |
ZA99693B (en) | 1999-10-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR014514A1 (en) | AN ISOLATED POLINUCLEOTIDE; AN ISOLATED POLYPEPTIDE CODED BY SUCH POLINUCLEOTIDE; AN EXPRESSION VECTOR THAT INCLUDES SUCH POLINUCLEOTIDE; A TRANSFORMED UNCELL WITH SUCH EXPRESSION VECTOR; A PHARMACEUTICAL COMPOSITION AND A VACCINE THAT UNDERSTAND THE POLYPEPTIDE FOR THE TREATMENT OF CANCE | |
TWI285648B (en) | Compositions and methods for WT1 specific immunotherapy | |
AR032173A1 (en) | CRYPT PROTEINS AND THEIR VARIANTS AS LYMPHOCYTARY EFFECTS AGAINST CANCER | |
ES2332590T3 (en) | PEPTIDIC DIMERO. | |
CA2158455A1 (en) | Immunogenic chimeras comprising nucleic acid sequences encoding endoplasmic reticulum signal sequence peptides and at least one other peptide and their uses in vaccines and disease treatments | |
RU2009117325A (en) | Fused Protein of Telomerase Reverse Transcriptase Encoding Its Nucleotides and Their Application | |
CY1113379T1 (en) | KDR Peptides and Vaccines Included | |
CA2230885A1 (en) | Compounds and methods for immunotherapy and diagnosis of tuberculosis | |
ES2398492T3 (en) | Fusion proteins comprising the tumor rejection antigens NY-ESO-1 and LAGE-1 | |
JP2019537562A5 (en) | ||
AR053372A1 (en) | IMMUNOLOGICAL PROTEINS OF LAWSONIA INTRACELLULARIS | |
DK0464124T3 (en) | Peptide, immunogenic composition and vaccine or medical preparation, method of immunizing a mammal against LHRH and method of improving the meat quality of pigs | |
US8309096B2 (en) | Fusion protein | |
ZA959416B (en) | Carrier protein having an adjuvant effect immunogenic complex containing it process for their preparation nuclofotide sequence and vaccine | |
KR102166549B1 (en) | A Blood-Brain Barrier Penetrating Peptide, and the Conjugate Comprising The Same | |
AR009365A1 (en) | FMD VIRUS VACCINES (FMDV), PEPTIDES, DNA SEQUENCES AND THE USE OF PEPTIDES IN DETECTION SYSTEMS AND THE USE OF FMDC VACCINE FOR PREPARATION OF A COMPOSITION TO IMMUNIZE PIGS AND CATTLE | |
KR970701724A (en) | Corpuscles of stannius protein (stanniocalcin) | |
PE20001287A1 (en) | PHARMACEUTICAL COMPOSITION CONTAINING DNA FRAGMENTS ENCODING AN ANTIGENIC PROTEIN WITH ANTITUMORAL EFFECT | |
CN100393356C (en) | Modified cytokines for use in cancer therapy | |
CA2353802A1 (en) | New protective antigen of group a streptococci | |
BR9908476A (en) | Peptide, therapeutic composition, and, process to confer protective immunity to a patient, against s infection. pneumoniae | |
HRP20110729T1 (en) | PLASMIDS CODING FOR p185neu PROTEIN SEQUENCE VARIANTS AND THERAPEUTIC USES THEREOF | |
CN1404527A (en) | TLP peptides and DNA sequences coding the same | |
NO20011263L (en) | Moraxella Catarrhalis BASBO34 polypeptides and uses thereof | |
AU2017236578A1 (en) | HCV vaccines |